Sickle cell disease — Africa’s need for new innovative treatment strategies

Written by Morayo

As the world continues to grapple with COVID-19, the weight of the pandemic is felt even more severely for those with underlying health conditions. Patients with pre-existing health conditions such as sickle cell disease (SCD) have been required to shield due to their increased vulnerability to the current virus. In African countries, the importance of protection for this vulnerable group cannot be stressed enough, as the healthcare system was already overstretched. SCD patients have always encountered difficulties seeking appropriate treatment and have been poorly managed in various African countries. Given the severity of symptoms, reduction in quality of life and low life expectancy, there is a huge demand for new strategies and treatments to improve the lives of those affected by sickle cell.

Sickle Cell Disease

Sickle cell disease is a blood condition highly prevalent in sub-Saharan Africa caused by a genetic mutation (1). Due to a genetic change on the HBB gene, red blood cells take on an abnormal form, which results in painful crisis episodes, anaemia, increased susceptibility to infections and high mortality rates. It is the most common life-threatening condition among those of African descent, however, it is also prevalent in India, the Mediterranean as well as the Middle East (2,3). Approximately 300,000–400,000 babies with sickle cell are born each year, of which nearly 75% are born in…